BR112022000297A2 - Conjugados de peptídeos de agentes de alvo de microtúbulos como terapêuticos - Google Patents

Conjugados de peptídeos de agentes de alvo de microtúbulos como terapêuticos

Info

Publication number
BR112022000297A2
BR112022000297A2 BR112022000297A BR112022000297A BR112022000297A2 BR 112022000297 A2 BR112022000297 A2 BR 112022000297A2 BR 112022000297 A BR112022000297 A BR 112022000297A BR 112022000297 A BR112022000297 A BR 112022000297A BR 112022000297 A2 BR112022000297 A2 BR 112022000297A2
Authority
BR
Brazil
Prior art keywords
therapeutics
targeting agents
peptide conjugates
microtubule targeting
microtubule
Prior art date
Application number
BR112022000297A
Other languages
English (en)
Inventor
Richard Marshall Daniel
Marie Csengery Johanna
A Volkmann Robert
John Maguire Robert
Original Assignee
Cybrexa 3 Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cybrexa 3 Inc filed Critical Cybrexa 3 Inc
Publication of BR112022000297A2 publication Critical patent/BR112022000297A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/04—1,3-Oxazines; Hydrogenated 1,3-oxazines
    • C07D265/12—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/537—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18—Bridged systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

conjugados de peptídeos de agentes de alvo de microtúbulos como terapêuticos. a presente invenção refere-se a conjugados de peptídeos de agentes de alvo de microtúbulos, tal como derivados de maitansinoides, que são úteis para o tratamento de doenças, tal como câncer.
BR112022000297A 2019-07-10 2020-07-09 Conjugados de peptídeos de agentes de alvo de microtúbulos como terapêuticos BR112022000297A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962872638P 2019-07-10 2019-07-10
US202063041324P 2020-06-19 2020-06-19
PCT/US2020/041348 WO2021007402A1 (en) 2019-07-10 2020-07-09 Peptide conjugates of microtubule-targeting agents as therapeutics

Publications (1)

Publication Number Publication Date
BR112022000297A2 true BR112022000297A2 (pt) 2022-03-15

Family

ID=71944331

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022000297A BR112022000297A2 (pt) 2019-07-10 2020-07-09 Conjugados de peptídeos de agentes de alvo de microtúbulos como terapêuticos

Country Status (17)

Country Link
US (2) US11555019B2 (pt)
EP (1) EP3996749A1 (pt)
JP (1) JP2022541747A (pt)
KR (1) KR20220051332A (pt)
CN (1) CN114302744A (pt)
AU (1) AU2020311925A1 (pt)
BR (1) BR112022000297A2 (pt)
CA (1) CA3146385A1 (pt)
CL (1) CL2022000043A1 (pt)
CO (1) CO2022001315A2 (pt)
CR (1) CR20220057A (pt)
EC (1) ECSP22010121A (pt)
IL (1) IL289659A (pt)
MX (1) MX2022000450A (pt)
PE (1) PE20220485A1 (pt)
TW (1) TW202116356A (pt)
WO (1) WO2021007402A1 (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3997093A1 (en) 2019-07-10 2022-05-18 Cybrexa 2, Inc. Peptide conjugates of cytotoxins as therapeutics
US20240093250A1 (en) 2021-01-08 2024-03-21 Cybrexa 2, Inc. Process for preparing a conjugate linking moiety
TW202330015A (zh) * 2021-11-17 2023-08-01 美商斯布雷克薩四號公司 作為治療劑之肽微管蛋白抑制劑之肽結合物

Family Cites Families (97)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5658920A (en) 1991-01-16 1997-08-19 Daiichi Pharmaceutical Co., Ltd. Substituted 1H,12H-benz-[DE]pyrano[3',4':6,7] indolizino[1,2-B]quinoline-10,13(9H,15H)-dione compound
US6504029B1 (en) 1995-04-10 2003-01-07 Daiichi Pharmaceutical Co., Ltd. Condensed-hexacyclic compounds and a process therefor
AU714873B2 (en) 1995-08-02 2000-01-13 Newcastle University Ventures Limited Benzimidazole compounds
EP0897924B1 (en) 1996-04-26 2001-10-31 Daiichi Pharmaceutical Co., Ltd. Process for the preparation of tetrahydro-indolizines
TW527183B (en) 1996-06-06 2003-04-11 Daiichi Seiyaku Co Drug complex
TW409058B (en) 1996-06-06 2000-10-21 Daiichi Seiyaku Co Method for preparation of a drug complex
IN189180B (pt) 1997-07-09 2003-01-04 Chong Kun Dang Corp
EA003398B1 (ru) 1998-05-22 2003-04-24 Дайити Фармасьютикал Ко., Лтд. Лекарственный комплекс c полимерным носителем
US6811996B1 (en) 1998-10-30 2004-11-02 Daiichi Pharmaceutical Co., Ltd. DDS compounds and method for assaying the same
ES2449713T3 (es) 1998-11-03 2014-03-20 Abbvie Deutschland Gmbh & Co Kg 2-fenilbencimidazoles sustituidos y su empleo como inhibidores de PARP
ATE261963T1 (de) 1999-01-11 2004-04-15 Agouron Pharma Tricyclische inhibitoren von poly(adp-ribose) polymerasen
DE19920936A1 (de) 1999-05-07 2000-11-09 Basf Ag Heterozyklisch substituierte Benzimidazole, deren Herstellung und Anwendung
ECSP003637A (es) 1999-08-31 2002-03-25 Agouron Pharma Inhibidores triciclicos de poli (adp-ribosa) polimerasas
US6699876B2 (en) 1999-11-18 2004-03-02 Les Laboratoires Servier Camptothecin analogue compounds
WO2001041534A2 (en) 1999-12-13 2001-06-14 Eli Lilly And Company Pseudomycin phosphate prodrugs
CA2401873A1 (en) * 2000-03-15 2001-09-20 Robert A. Copeland Peptidase-cleavable, targeted antineoplastic drugs and their therapeutic use
US6815435B2 (en) 2000-07-13 2004-11-09 Daiichi Pharmaceutical Co., Ltd. Pharmaceutical compositions containing DDS compounds
US7151102B2 (en) 2000-10-30 2006-12-19 Kudos Pharmaceuticals Limited Phthalazinone derivatives
EP1487493B1 (en) 2002-03-01 2010-01-20 The Administrators of The Tulane Educational Fund Conjugates of cytotoxic agents and biologically active peptides
KR100951499B1 (ko) 2002-03-20 2010-04-07 브리스톨-마이어스 스큅 컴퍼니 플루오로옥신돌의 포스페이트 전구약물
JP4500161B2 (ja) 2002-04-30 2010-07-14 クドス ファーマシューティカルズ リミテッド フタラジノン誘導体
US7449464B2 (en) 2003-03-12 2008-11-11 Kudos Pharmaceuticals Limited Phthalazinone derivatives
MXPA05010563A (es) 2003-03-31 2005-11-23 Pfizer Sales de los inhibidores triciclicos de las poli(adp-ribosa) polimerasas.
KR101424624B1 (ko) 2003-05-14 2014-07-31 이뮤노젠 아이엔씨 약물 콘쥬게이트 조성물
US8088387B2 (en) 2003-10-10 2012-01-03 Immunogen Inc. Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates
PT3524611T (pt) 2003-05-20 2021-04-01 Immunogen Inc Agentes citotóxicos melhorados compreendendo novos maitansinóides
US7276497B2 (en) 2003-05-20 2007-10-02 Immunogen Inc. Cytotoxic agents comprising new maytansinoids
DK1660095T3 (da) 2003-07-25 2010-05-25 Cancer Rec Tech Ltd Tricykliske PARP-inhibitorer
GB0317466D0 (en) 2003-07-25 2003-08-27 Univ Sheffield Use
RU2413515C2 (ru) 2003-12-01 2011-03-10 Кудос Фармасьютикалс Лимитед Ингибиторы репарации повреждения днк для лечения рака
WO2005082023A2 (en) 2004-02-23 2005-09-09 Genentech, Inc. Heterocyclic self-immolative linkers and conjugates
WO2006012527A1 (en) 2004-07-23 2006-02-02 Endocyte, Inc. Bivalent linkers and conjugates thereof
NZ553295A (en) 2004-09-22 2010-04-30 Pfizer Therapeutic combinations comprising poly(ADP-ribose) polymerases inhibitor
SI1794163T1 (sl) 2004-09-22 2010-04-30 Pfizer Postopek priprave inhibitorjev poli(ADP-riboza) polimeraz
EP1799685B1 (en) 2004-09-22 2012-03-28 Pfizer Inc. Polymorphic forms of the phosphate salt of 8-fluoro-2-{4-[(methylamino)methyl]phenyl}-1,3,4,5-tetrahydro-6h-azepino[5,4,3-cd]indol-6-one
NZ555601A (en) 2004-12-09 2009-07-31 Centocor Inc Anti-integrin immunoconjugates, methods and uses
AU2006206428B2 (en) 2005-01-18 2009-07-16 The Board Of Governors For Higher Education Selective delivery of molecules into cells or marking of cells in diseased tissue regions using environmentally senstive transmembrane peptide
US7301019B2 (en) 2005-01-21 2007-11-27 Immunogen, Inc. Method for the preparation of maytansinoid esters
EP1853322B1 (en) 2005-02-11 2014-06-25 ImmunoGen, Inc. Process for preparing maytansinoid antibody conjugates
JP2008538365A (ja) 2005-04-15 2008-10-23 イミュノジェン・インコーポレーテッド 腫瘍内の不均一または混合細胞集団を排除する方法
AU2006283726C1 (en) 2005-08-24 2015-05-07 Immunogen, Inc. Process for preparing maytansinoid antibody conjugates
ES2378692T3 (es) 2005-09-29 2012-04-17 Abbott Laboratories Las 1H-benzimidazol-4-carboxamidas sustituidas con fenilo en la posición 2 son potentes inhibidores de PARP
PL1945647T3 (pl) 2005-11-08 2012-04-30 Immunogen Inc Procesy wytwarzania maytansinolu
RS53082B (en) 2006-01-17 2014-06-30 Abbvie Bahamas Ltd. COMBINED THERAPY WITH PARP INHIBITORS
TWI404716B (zh) 2006-10-17 2013-08-11 Kudos Pharm Ltd 酞嗪酮（ｐｈｔｈａｌａｚｉｎｏｎｅ）衍生物
EP2336120B1 (en) 2007-01-10 2014-07-16 MSD Italia S.r.l. Combinations containing amide substituted indazoles as poly(adp-ribose)polymerase (parp) inhibitors
WO2008114114A2 (en) 2007-03-16 2008-09-25 Pfizer Products Inc. Poly(adp-ribose) polymerases inhibitor for treating ophthalmic condition
WO2009002993A1 (en) 2007-06-25 2008-12-31 Endocyte, Inc. Conjugates containing hydrophilic spacer linkers
US8067613B2 (en) 2007-07-16 2011-11-29 Abbott Laboratories Benzimidazole poly(ADP ribose)polymerase inhibitors
PL2187965T3 (pl) 2007-08-17 2020-05-18 Purdue Research Foundation Koniugaty wiążący psma ligand-łącznik i sposoby ich zastosowania
KR20100137585A (ko) 2008-04-30 2010-12-30 이뮤노젠 아이엔씨 강력한 복합체 및 친수성 링커
SG10201810743WA (en) 2009-06-03 2018-12-28 Immunogen Inc Conjugation methods
US9353140B2 (en) 2009-11-25 2016-05-31 Academia Sinica BQC-G, a tumor-selective anti-cancer prodrug
US8754072B2 (en) 2010-02-12 2014-06-17 Pfizer Inc. Salts and polymorphs of 8-fluoro-2-{4-[(methylamino)methyl]phenyl}-1,3,4,5-tetrahydro-6h-azepino[5,4,3-cd]indol-6-one
US20120322741A1 (en) 2010-02-25 2012-12-20 Purdue Research Foundation Psma binding ligand-linker conjugates and methods for using
JP2013527145A (ja) 2010-03-31 2013-06-27 ギリード・ファーマセット・エルエルシー リン含有活性化剤の立体選択的合成
US8754190B2 (en) 2010-05-05 2014-06-17 Prolynx Llc Controlled release from macromolecular conjugates
CA3032186C (en) * 2010-07-13 2022-04-26 Council on Postsecondary Education, State of Rhode Island and Providence Plantations Environmentally sensitive composition comprising a ph triggered peptide and uses thereof
EP2603201B1 (en) 2010-08-13 2020-03-11 Rhode Island Board of Governors for Higher Education Liposome compositions and methods of use thereof
MX2013005046A (es) 2010-11-03 2013-12-12 Immunogen Inc Agentes citotoxicos que comprenden nuevos derivados de ansamitocina.
SI2691155T1 (sl) 2011-03-29 2019-03-29 Immunogen, Inc. Priprava majtanzinoidnih konjugatov protiteles v postopku z enim korakom
SG193997A1 (en) 2011-03-29 2013-11-29 Immunogen Inc Process for manufacturing conjugates of improved homogeneity
HUE025661T2 (en) 2011-10-14 2016-04-28 Medimmune Ltd Pyrrolobenzodiazepines and their conjugates
KR102087017B1 (ko) 2012-10-11 2020-03-10 다이이찌 산쿄 가부시키가이샤 항체-약물 콘주게이트
EP2910573B1 (en) 2012-10-19 2020-02-19 Daiichi Sankyo Company, Limited Antibody-drug conjugate produced by binding through linker having hydrophilic structure
US9180203B2 (en) 2012-10-23 2015-11-10 The Johns Hopkins University Self-assembling drug amphiphiles and methods for synthesis and use
US9919059B2 (en) 2012-12-10 2018-03-20 Massachusetts Institute Of Technology Multistage nanoparticle drug delivery system for the treatment of solid tumors
EP2961434A2 (en) 2013-02-28 2016-01-06 ImmunoGen, Inc. Conjugates comprising cell-binding agents and cytotoxic agents
IL290330B2 (en) 2013-12-19 2023-09-01 Seagen Inc Methylene carbamate binders for use with drug-targeting conjugates
US20180163271A1 (en) 2014-01-16 2018-06-14 Clovis Oncology, Inc. Use of PARP Inhibitors to Treat Breast or Ovarian Cancer Patients Showing a Loss of Heterozygosity
JP2017114763A (ja) 2014-03-26 2017-06-29 第一三共株式会社 抗ｃｄ９８抗体−薬物コンジュゲート
CN111228511B (zh) 2014-04-10 2024-06-18 第一三共株式会社 抗her3抗体-药物偶联物
US11185594B2 (en) 2014-04-10 2021-11-30 Daiichi Sankyo Company, Limited (Anti-HER2 antibody)-drug conjugate
CN106794185A (zh) 2014-08-22 2017-05-31 克洛维斯肿瘤有限公司 Rucaparib的高剂量强度片剂
PL3110447T3 (pl) 2014-09-16 2020-10-19 Synermore Biologics Co., Ltd. Przeciwciało anty-EGFR i jego zastosowania
US10413615B2 (en) 2014-11-19 2019-09-17 Immunogen, Inc. Process for preparing cell-binding agent-cytotoxic agent conjugates
MA43354A (fr) 2015-10-16 2018-08-22 Genentech Inc Conjugués médicamenteux à pont disulfure encombré
TWI703147B (zh) 2015-11-24 2020-09-01 美商施萬生物製藥研發Ｉｐ有限責任公司 用於治療胃腸發炎性疾病之jak抑制劑化合物之前藥
KR102498258B1 (ko) 2016-01-20 2023-02-10 삼성디스플레이 주식회사 표시 장치
US20170267727A1 (en) 2016-03-04 2017-09-21 Lehigh University Conjugates of pH Low Insertion Peptide and Monomethyl Auristatins in the Treatment of Solid Tumors
JP2019510085A (ja) 2016-03-08 2019-04-11 ロス ガトス ファーマスーティカルズ， インク．Ｌｏｓ Ｇａｔｏｓ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 癌治療のためのナノ粒子ならびに方法および化合物
US20200078468A1 (en) 2016-04-13 2020-03-12 Tarveda Therapeutics, Inc. Neurotensin receptor binding conjugates and formulations thereof
GB201608885D0 (en) 2016-05-20 2016-07-06 Univ Birmingham Treatment
WO2017210608A1 (en) 2016-06-02 2017-12-07 Yale University Compositions and methods for targeting and treating homologous recombination-deficient tumors
WO2018023098A1 (en) * 2016-07-29 2018-02-01 Memorial Sloan Kettering Cancer Center Radiolabeled ligands for targeted pet/spect imaging and methods of their use
MX2019001905A (es) 2016-08-16 2019-05-15 Aist Peptido objetivo de tumor maligno.
JP7181875B2 (ja) * 2016-09-22 2022-12-01 ユニバーシティー オブ ロード アイランド ボード オブ トラスティーズ ｐＨトリガーポリペプチドにコンジュゲートしたフルオロフォアを含む蛍光化合物
EP3634498A4 (en) 2017-06-09 2021-08-25 Rhode Island Council on Postsecondary Education CONNECTED AND OTHER PH-RIGIDED CONNECTIONS
CN117838880A (zh) 2017-08-31 2024-04-09 第一三共株式会社 制备抗体-药物缀合物的新方法
MX2020007060A (es) 2018-01-05 2020-11-11 Cybrexa 1 Inc Compuestos, composiciones y metodos para tratar enfermedades que involucren tejidos con enfermedades acidas o hipoxicas.
AU2019206623A1 (en) 2018-01-12 2020-07-16 Prolynx Llc Synergistic cancer treatment
CN117815404A (zh) 2018-05-18 2024-04-05 第一三共株式会社 抗-muc1抗体-药物缀合物
TW202015740A (zh) 2018-06-07 2020-05-01 美商西雅圖遺傳學公司 喜樹鹼結合物
CN109232719B (zh) 2018-09-21 2021-06-29 中国科学院理化技术研究所 一种pH响应的抗菌肽及其制备方法和应用
WO2020160009A1 (en) * 2019-01-28 2020-08-06 Rhode Island Council On Postsecondary Education Phlip® targeted delivery of potent cytotoxic compounds
CN118240003A (zh) 2019-03-29 2024-06-25 免疫医疗有限公司 化合物及其缀合物
EP3997093A1 (en) 2019-07-10 2022-05-18 Cybrexa 2, Inc. Peptide conjugates of cytotoxins as therapeutics

Also Published As

Publication number Publication date
CN114302744A (zh) 2022-04-08
CL2022000043A1 (es) 2022-08-19
WO2021007402A1 (en) 2021-01-14
EP3996749A1 (en) 2022-05-18
CR20220057A (es) 2022-07-19
ECSP22010121A (es) 2022-05-31
CO2022001315A2 (es) 2022-05-10
AU2020311925A1 (en) 2022-02-03
JP2022541747A (ja) 2022-09-27
PE20220485A1 (es) 2022-04-04
MX2022000450A (es) 2022-04-25
US20210009536A1 (en) 2021-01-14
IL289659A (en) 2022-03-01
TW202116356A (zh) 2021-05-01
US20240067616A1 (en) 2024-02-29
CA3146385A1 (en) 2021-01-14
US11555019B2 (en) 2023-01-17
KR20220051332A (ko) 2022-04-26

Similar Documents

Publication Publication Date Title
BR112022000337A2 (pt) Conjugados de peptídeos de citotoxinas como terapêuticos
CY1123983T1 (el) Ειδικα σε axl συζευγματα αντισωματος-φαρμακου για τη θεραπεια καρκινου
ZA201906111B (en) Cyclic di-nucleotides compounds for the treatment of cancer
BR112022000297A2 (pt) Conjugados de peptídeos de agentes de alvo de microtúbulos como terapêuticos
WO2018140831A3 (en) Tumor targeting conjugates and methods of use thereof
BR112016029916A2 (pt) inibidores mnk e métodos correlatos
EA202190189A1 (ru) Сшитое производное димера пирролобензодиазепина (pbd) и его конъюгаты
MX2017003246A (es) Macropinocitosis de anticuerpos anti-cd46 humanos y agentes terapeuticos dirigidos contra el cancer.
BR112017012377A2 (pt) conjugados anticorpo-fármaco com inibidores de bcl-xl permeáveis à célula
BR112021024236A2 (pt) Proteínas multiespecíficas
MX2018011627A (es) Profarmacos de farmacos citotoxicos que tienen grupos enzimaticamente escindibles.
BR112018074268A2 (pt) pastas dentais terapêuticas e métodos e kits relacionados
MX371092B (es) Compuestos peptidomimeticos y conjugados de anticuerpo-farmaco de los mismos.
CU20190072A7 (es) Conjugados de fármacos y anticuerpos anti-ccr7
UY36075A (es) Derivados de tubulisina
PH12019550140A1 (en) Piperidine-substituted mnk inhibitors and methods related thereto
AR104987A1 (es) Inmunoconjugados anticuerpo-fármaco unidos por enlazadores no peptídicos
ECSP20061378A (es) COMPUESTOS DIÓLICOS DE AMINOPIRAZINA COMO INHIBIDORES DE PI3K-gamma
CO2019002523A2 (es) Inhibidores de dopamina–β–hidroxilasa penetrantes de la barrera hematoencefálica
CU24493B1 (es) Complejo de torio dirigido a tejido
PH12018502473A1 (en) Pegylated carfilzomib compounds
EA201991196A1 (ru) Претерпевшие самосборку диблок-сополимеры, состоящие из pegmema и несущих лекарственное средство полимерных сегментов
BR112022005026A2 (pt) Conjugados terapêuticos
MX2020003089A (es) Analogos de tailanstatina.
AU2018275686A1 (en) Precipitation resistant small molecule drug formulations